Effects of different KRAS mutants and Ki67 expression on diagnosis and prognosis in lung adenocarcinoma
Open Access
- 19 February 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-11
Abstract
Lung adenocarcinoma (LUAD) is a prevalent form of non-small cell lung cancer with a rising incidence in recent years. Understanding the mutation characteristics of LUAD is crucial for effective treatment and prediction of this disease. Among the various mutations observed in LUAD, KRAS mutations are particularly common. Different subtypes of KRAS mutations can activate the Ras signaling pathway to varying degrees, potentially influencing the pathogenesis and prognosis of LUAD. This study aims to investigate the relationship between different KRAS mutation subtypes and the pathogenesis and prognosis of LUAD. A total of 63 clinical samples of LUAD were collected for this study. The samples were analyzed using targeted gene sequencing panels to obtain sequencing data. To complement the dataset, additional clinical and sequencing data were obtained from TCGA and MSK. The analysis revealed significantly higher Ki67 immunohistochemical scores in patients with missense mutations compared to controls. Moreover, the expression level of KRAS was found to be significantly correlated with Ki67 expression. Enrichment analysis indicated that KRAS missense mutations activated the SWEET_LUNG_CANCER_KRAS_DN and CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_2 pathways. Additionally, patients with KRAS missense mutations and high Ki67 IHC scores exhibited significantly higher tumor mutational burden levels compared to other groups, which suggests they are more likely to be responsive to ICIs. Based on the data from MSK and TCGA, it was observed that patients with KRAS missense mutations had shorter survival compared to controls, and Ki67 expression level could more accurately predict patient prognosis. In conclusion, when utilizing KRAS mutations as biomarkers for the treatment and prediction of LUAD, it is important to consider the specific KRAS mutant subtypes and Ki67 expression levels. These findings contribute to a better understanding of LUAD and have implications for personalized therapeutic approaches in the management of this disease.Keywords
This publication has 49 references indexed in Scilit:
- Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and reviewOncotarget, 2017
- A combinatorial strategy for treating KRAS-mutant lung cancerNature, 2016
- A systematic study on drug-response associated genes using baseline gene expressions of the Cancer Cell Line EncyclopediaScientific Reports, 2016
- The clinical relevance of KRAS gene mutation in non-small-cell lung cancerCurrent Opinion in Oncology, 2014
- KRAS Mutations in Lung CancerClinical Lung Cancer, 2013
- A Comprehensive Survey of Ras Mutations in CancerCancer Research, 2012
- Drug development and clinical trials—the path to an approved cancer drugNature Reviews Clinical Oncology, 2012
- KRAS Mutations in Non-Small Cell Lung CancerProceedings of the American Thoracic Society, 2009
- Biochemical and Functional Characterization of Germ Line KRAS MutationsMolecular and Cellular Biology, 2007
- Constructing Molecular Classifiers for the Accurate Prognosis of Lung AdenocarcinomaClinical Cancer Research, 2006